Chemoprophylaxis and Viruses of the Respiratory Tract: Some New Approaches to Antiviral Chemotherapy, Metalloenzyme Inhibition, and Transport by Liposomes

2018 ◽  
pp. 201-217
Author(s):  
Michael J. Clemens ◽  
D. D. Perrin
Keyword(s):  
Respiratory Tract ◽  
New Approaches ◽  
Antiviral Chemotherapy

scholarly journals NEW APPROACHES TO RESPIRATORY TRACT DOSIMETRY MODELING FOR INHALED RADIONUCLIDES

1988 ◽  
pp. 851-863
Author(s):  
R.G. CUDDIHY ◽  
G.L. FISHER ◽  
O.R. MOSS ◽  
R.F. PHALEN ◽  
R.B. SCHLESINGER ◽  
...  
Keyword(s):  
Respiratory Tract ◽  
New Approaches

BIOLOGIC SIGNIFICANCE OF THE SECRETORY γA IMMUNOGLOBULINS

PEDIATRICS ◽  
1971 ◽  
Vol 48 (5) ◽  
pp. 715-729
Author(s):  
Joseph A. Bellanti
Keyword(s):  
Respiratory Tract ◽  
Natural Infection ◽  
Resistance Mechanisms ◽  
Local Application ◽  
Viral Antigens ◽  
Attenuated Vaccine ◽  
New Approaches ◽  
Secretory System

The secretory γA globulins have been shown to be the active antiviral neutralizing principle in the respiratory tract. These antibodies are part of the system found in other fluids in contiguity with the exterior, the external secretory system. The presence of these γA associated antibodies has been shown to be correlated with protection particularly in the case of certain infections which are localized in their pathogenesis. The production of these antibodies are favored by either natural infection, attenuated vaccine, or by local application of viral antigens directly to the respiratory tract. When this system is inappropriately stimulated, hypersensitivity phenomena may occur. Finally, these observations suggest that the secretory γA globulins serve as a basis for an understanding of resistance mechanisms in the normal, and for the development of new approaches to the use of vaccines.

Hepatitis B: New Approaches for Antiviral Chemotherapy

1996 ◽  
Vol 7 (2) ◽  
pp. 53-64 ◽  
Author(s):  
S. A. Locarnini ◽  
G. M. Civitico ◽  
J. E. Newbold
Keyword(s):  
Hepatitis B ◽  
Supercoiled Dna ◽  
Treatment Regimes ◽  
Lead Compounds ◽  
New Approaches ◽  
B Virus ◽  
Antiviral Chemotherapy ◽  
Effective Development ◽  
Important Disease

Progress in the development of effective therapeutic regimes for chronic hepatitis B has been slow, mainly due to the lack of promising lead compounds and useful assays for high throughput in-vitro screening. Nucleoside analogue chemotherapy has targeted the inhibition of the hepatitis B virus (HBV) polymerase and achieved inhibition of this unique viral enzyme. The persistence and resistance of HBV covalently closed circular (or supercoiled) DNA, the key replicative intermediate and sole transcriptional template, to existing treatments also poses challenges for the effective development of antiviral chemotherapy. In spite of these difficulties, the process of viral DNA replication, as well as supercoiled DNA generation and processing, is now being elucidated at the molecular level, presenting unique opportunities for new drug targeting and design. This review attempts to highlight these new approaches to the development of treatment regimes for this important disease.

Scientific Report: Highlights of 24th ICAR, 8–11 May 2011, Sofia, Bulgaria

2011 ◽  
Vol 22 (2) ◽  
pp. 75-85 ◽  
Author(s):  
Anthony Vere Hodge
Keyword(s):  
Clinical Trials ◽  
Clinical Results ◽  
Keynote Address ◽  
Emerging Viruses ◽  
Lethal Mutagenesis ◽  
New Approaches ◽  
Antiviral Compounds ◽  
Scientific Report ◽  
Antiviral Chemotherapy ◽  
New Research

The 24th ICAR meeting was held in Sofia, Bulgaria, 8–11 May 2011. This report summarizes the presentations by the ICAR award winners, Earl Kern and Brian Gowen; the keynote address by Albert (ADME) Osterhaus; the Plenary lectures by Raina Fichorova, Ralf Bartenschlager and Esteban Domingo; the invited speakers for the symposia; and a few of those by contributors. This report aims to reflect the diversity of topics across different disciplines (chemistry to biology) discussed at ICAR: old viruses (smallpox), emerging viruses (SARS, new strains of influenza and flaviviruses), problematic viruses (HIV and HCV), sporadic viruses (arenaviruses), neglected viruses (enteroviruses), new research targets (for HCV) and new approaches (lethal mutagenesis). There were timely reports on promising compounds against adenoviruses, cytomegalovirus, HCV and HIV in clinical trials. This conference illuminated the constantly evolving field of antiviral chemotherapy by providing a forum to present and discuss new antiviral compounds, new uses for old compounds and exciting clinical results. This ICAR was a fitting testament to the ‘father of antiviral chemotherapy’, Bill Prusoff, who died aged 90 in April 2011.

scholarly journals NEW APPROACHES TO RESPIRATORY TRACT DOSIMETRY MODELING FOR INHALED RADIONUCLIDES

1988 ◽  
pp. 833-841 ◽  
Author(s):  
R.G. CUDDIHY ◽  
G.L. FISHER ◽  
O.R. MOSS ◽  
R.F. PHALEN ◽  
R.B. SCHLESINGER ◽  
...  
Keyword(s):  
Respiratory Tract ◽  
New Approaches

Beyond autism: Challenging unexamined assumptions about social motivation in typical development

2019 ◽  
Vol 42 ◽  
Author(s):  
Karen Bartsch ◽  
David Estes
Keyword(s):  
Social Interest ◽  
Social Motivation ◽  
Typical Development ◽  
Typically Developing ◽  
New Approaches

Abstract In challenging the assumption of autistic social uninterest, Jaswal & Akhtar have opened the door to scrutinizing similar unexamined assumptions embedded in other literatures, such as those on children's typically developing behaviors regarding others’ minds and morals. Extending skeptical analysis to other areas may reveal new approaches for evaluating competing claims regarding social interest in autistic individuals.

Sign in / Sign up

Export Citation Format

Share Document